Helixmith Co Ltd
KOSDAQ:084990
Helixmith Co Ltd
Other
Helixmith Co Ltd
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Helixmith Co Ltd
KOSDAQ:084990
|
Other
-₩26.4m
|
CAGR 3-Years
72%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Other
₩1.5T
|
CAGR 3-Years
163%
|
CAGR 5-Years
41%
|
CAGR 10-Years
28%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Other
-₩60.8m
|
CAGR 3-Years
28%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Other
-₩23m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Other
-₩55.4m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
Helixmith Co Ltd
Glance View
Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-29. The firm operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
See Also
What is Helixmith Co Ltd's Other?
Other
-26.4m
KRW
Based on the financial report for Sep 30, 2025, Helixmith Co Ltd's Other amounts to -26.4m KRW.
What is Helixmith Co Ltd's Other growth rate?
Other CAGR 5Y
63%
Over the last year, the Other growth was 100%. The average annual Other growth rates for Helixmith Co Ltd have been 72% over the past three years , 63% over the past five years .
